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Abstract 
 
Objective: Paraneoplastic neurological syndromes (PNS) probably result from an immune reaction 
against antigens shared by the nervous system and tumour cells. To characterize CSF alterations in 
these syndromes, we studied a large series of paraneoplastic patients. 
 
Methods:  Using the PNS European database which includes patients diagnosed with PNS in Europe, 
we reviewed the clinical data of all patients included between 2000 and 2007 for which information on 
the CSF was available. Patients were studied if they met the following inclusions criteria: a) definite 
paraneoplastic disease with anti-Hu, anti-Yo, anti-CV2, anti-Ri anti-Ma/Ta and anti-Tr antibodies; b) 
clinical information available; c) at least 1 CSF study. 
 
Results: 295 patients met the inclusion criteria. Abnormal CSF (pleiocytosis and/or high protein level 
and/or oligoclonal bands) was found in 93% of the patients. Pleiocytosis, but not hyperproteinorachia, 
was more frequently seen in patients in whom the CSF study was done early in the evolution. In 24 
patients, OCB were the only abnormality found in the CSF (10%). Elevated numbers of cells were found 
in 47% of the patients before the 3
rd
 month, vs 28% after the 3
rd
 month (p<0.01). This evolution might 
suggest a sub-acute inflammation phase within the nervous system, followed by a non-inflammatory 
phase. The inflammation profile was similar in all antibody types, cancers or neurological syndromes of 
the PNS. Surprisingly, anti-Hu patients with high pleiocytosis at time of diagnostic had a better survival 
in this study than those without pleiocytosis, (572 days vs 365 days, p=0.05) 
 
Conclusion: CSF inflammation is a common finding in PNS patient and can be a helpful tool for the 
diagnosis, especially if this analysis is done within 3 months after neurological onset.  
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Introduction  
 
Paraneoplastic neurological syndromes (PNS) are characterized by inflammation of the nervous 
system, indolent tumor growth and an immune reaction against antigens shared by the nervous system 
and the tumor cells (Dalmau and Posner, 1999). Antibodies (Abs) against these antigens are sometimes 
identified in the patients’ sera and are strongly associated with paraneoplastic syndromes (Dalmau et al, 
1992, Luque et al, 1991, Rosenfeld et al, 2001, Peltola et al, 1998, Peterson et al, 1992, Graus et al, 
2001, Honnorat et al, 1996).  
 
Abnormalities of the cerebro-spinal fluid (CSF) have been reported in paraneoplastic patients, 
and probably reflect the inflammatory nature of these diseases. However, the frequency, the relationship 
with clinical features and the evolution over time of the CSF abnormalities have never been thoroughly 
described. We therefore studied CSF features in a large series of paraneoplastic patients with anti-Hu, 
anti-Yo, anti-CV2, anti-Ri anti-Ma/Ta and anti-Tr antibodies. 
 
 
 
Patients and Methods 
 
The PNS European database includes patients diagnosed with PNS in Europe after 2000. The 
database records information on the neurological symptoms, tumour diagnosis, treatments and 
outcome.  
 
We reviewed the clinical data of all patients included in this PNS European database before 
November 2007, for whom CSF information was available. Patients were studied if they met the 
following inclusion criteria: a) definite paraneoplastic disease with anti-Hu, anti-Yo, anti-CV2, anti-Ri 
anti-Ma/Ta or anti-Tr antibodies in the serum; b) clinical information available (type of neurological 
syndrome, date of neurological onset) c) at least 1 CSF study with records of cell count (white 
cells/mm3: normal ≤ 5 wc/mm3) and protein content (mg/dl: normal between 20 and 50 mg/dl). When 
available, presence of oligoclonal bands (OCB) in the CSF was collected, although the paired serum 
OCB status was usually not stated in the medical records. In patients who had several lumbar 
punctures, only the first CSF study was considered for the global analysis.  
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Neurological syndromes were classified as limbic encephalitis, encephalomyelitis, cerebellar 
degeneration, brainstem encephalitis (including opsoclonus) and peripheral nerve disorders (sensory 
neuronopathy, polyneuropathy, chronic inflammatory demyelinating polyneuropathy, Guillain Barre 
syndrome, dysautonomia, and motor neuron disease), following the diagnostic criteria of the PNS 
Euronetwork (Graus for the PNS Euronetwork, 2004). Tumors were classified as small cell lung 
carcinoma (SCLC), non small cell lung carcinoma (NSCLC), breast cancer, testicular cancer, 
gynecological (ovary and uterus) cancer, Hodgkin diseases, and others. 
 
The categorical variables were expressed by proportions and the continuous ones were 
described with mean, median and inter-quartile range. The Pearson chi-square test was used to 
compare qualitative variables while the Mann-Whitney-Wilcoxon rank test was used for quantitative 
ones. Survival analysis was performed through Kaplan–Meier method to compare patients with normal 
vs. abnormal cell count. Differences in survival time from syndrome onset were evaluated through the 
Log-Rank test. All tests were two-tailed, with 0.05 as the level of significance. Data were analyzed using 
SAS software (version 9.02, SAS System, Cary, NC). 
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Results  
 
 
Out of 829 patients registered in the database in November 2007, 295 patients met the 
inclusion criteria. The patients’ characteristics are summarized in table 1 and 2. The most frequent 
antibody was anti-Hu (58%) followed by anti-Yo (20%), anti-CV2 (8%), anti-Ma/Ta (6%), anti-Ri (5%) 
and anti-Tr (3%). Among the 170 patients with anti-Hu Abs, 9 had anti-CV2 Abs, 8 had anti-Ri Abs, 5 
also had anti-amphiphysine Abs, one had anti-VGCC Abs, two had anti-Yo Abs, one had anti-Tr Abs 
and 5 had other or atypical Abs. Most patients with anti-Hu Abs had peripheral nerve disorders and 
SCLC (44% and 64%, respectively) (Appendix 1 and 2). Cerebellar degeneration was the main clinical 
syndrome in anti-Yo (92%) and anti-Tr (89%) patients. PEM was almost always associated with anti-Hu 
antibodies (91%) and very often with SCLC tumours (72%). The frequency of brainstem encephalitis 
was higher in anti-Ri group (60%) and limbic encephalitis in anti-Ma/Ta group (58%). No tumour was 
found in 41 patients (14 %).  
 
Table 1 
 
 Anti-Hu Anti-Yo Anti-CV2 Anti-Ma/Ta Anti-Ri Anti-Tr 
N 170 59 23 19 15 9 
F/M 67/103 57/2 7/16 4/15 12/3 2/7 
Mean age (Sd : Q1-Q3) 66 (58-72) 65 (59-72) 68 (61-78) 55 (42-69) 66 (52-75) 58 (50-71) 
Neurological syndrome       
-peripheral nerve 
disorders 
74 1 9 0 0 0 
-limbic encephalitis 14 0 1 11 3 1 
-Brainstem encephalitis 16 1 0 4 9 0 
-Cerebellar degeneration 12 54 3 3 3 8 
-PEM 29 1 2 0 0 0 
-Other 25 2 8 1 0 0 
Cancer        
-SCLC 109 0 12 0 0 0 
-NSCLC 11 1 2 1 1 0 
-Testicular 0 0 0 6 1 0 
-Breast 4 11 1 2 8 0 
-Gynaecological 0 32 0 0 0 0 
-Hodgkin 0 0 0 0 0 6 
-No tumour 23 5 4 6 2 1 
-Others 23 10 4 4 3 2 
 
Cells were studied in 290 patients and found to be superior to 5 wc/mm3 in 112 patients (39%) 
(median cell level: 3 wc/mm3). Proteins were studied in 281 patients and found to be higher than 50 
mg/dl in 187 patients (67 %) (median protein level: 68 mg/dl). Presence of oligoclonal bands (OCB) in 
the CSF was studied in 135 patients and found positive in 85 patients (63%). In 24 patients, OCB were 
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the only abnormality found in the CSF (10%).  In patients in whom pleiocytosis, proteinorachia and 
oligoclonal bands where all studied, completely normal CSF was found in only 7% of patients (18/260).  
 
Table 2 
 
 Anti-Hu  Anti-Yo Anti-CV2 Anti-Ma/Ta Anti-Ri Anti-Tr 
N 170 59 23 19 15 9 
Abnormal (%) 93% (140/151) 96% (51/53) 95% (20/21) 87% (13/15) 100% (13/13) 71% (5/7) 
Median delay after 
clinical onset (Q1-Q3) 
79 days (27-166) 76 days (31-184) 66 days (22-147) 106 days (30-243) 84 days (16-125) 44 (29-109) 
Median number of cells 
(Q1-Q3) 
3 (1-8) 4 (1-22) 5 (1-12) 3 (1-20) 5 (1-15) 7 (3-10) 
Median number of protein 
(Q1-Q3) 
78 (49-135) 54 (36-80) 75 (57-100) 53 (39-70) 55 (39-415) 41 (25-72) 
Positive oligoclonal 
bands 
43/73 25/33 6/8 5/10 6/8 0/3 
 
 
To describe the CSF abnormalities over time, we plotted the cell and the protein values on the 
y-axis and the delay from neurological onset to the CSF study on the x-axis, in patients who did not 
receive any treatment before the CSF study (n=206) (Figure 1). The CSF study was done within the first 
3 months after neurological onset in 162 patients. Elevated numbers of white cells were found in 47% of 
these patients, versus 28% after the 3
rd
 month (Pearson chi-square test, p<0.01). The median level was 
5 cells/mm3 before the 3
rd
 month and 2 cells/mm3 after (Mann-Whitney-Wilcoxon test, p<0.01). 
Hyperproteinorachia was observed in 71% of the patients (median 73 mg/dl) before the 3
rd
 month and in 
61% (median 59 mg/dl) after the 3
rd
 month (Mann-Whitney-Wilcoxon test, p<0.01). OCB were found in 
63% (42 out of 67) of the patients and the same after the 3d month (43 out of 68). Within 3 months from 
neurological onset, in patients in whom pleiocytosis, proteinorachia and oligoclonal bands were all 
studied, completely normal CSF was found in only in 3% of the patients (11.9% of the patients of 
completely normal CSF after 3 months from neurological onset). 
 
To further study the possible decrease over time of pleiocytosis, we focused on the few patients 
who had repeated CSF studies without any treatment between two CSF tests. There were 15 patients 
with both CSF studies done before day 90, and 17 patients in whom the second CSF study was done 
after day 90 (appendix 5). The median time point of the first CSF study was 18 and 87 days respectively 
for both groups. The pleiocytosis appeared or increased in 7 patients out of 15 when both CSF studies 
were made before the first 3 months, but only in 1 patient out of 17 when the second lumbar puncture 
was done after the first 3 months (p=0.009). Similarly, when the analysis was limited to the 23 patients 
showing at least one abnormal CSF, the decrease in pleiocytosis was more frequent when the second 
CSF study was done after the first 3 months (p=0.03) 
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To investigate whether oncological or immunological treatments could impact CSF 
abnormalities, we looked at the 12 patients who had two CSF studies and were treated in between. The 
difference between cells and proteins before and after treatment was not statistically significant (median 
cell level: 9 cells/mm3 before treatment and 4.5 cells/mm3 after treatment; median protein level: 86 
mg/dl before treatment and 86 mg/dl after treatment). 
 
 
We then focused on the pattern of CSF abnormalities within 3 months, depending upon the 
antibody or the cancer types. Surprisingly, no significant difference was seen in the protein levels or in 
the cell reaction among the various antibodies or cancers, although there was a trend for higher protein 
levels in patients with anti-Hu and anti-CV2 Abs or lung cancer (SCLC and NSLC). See appendix 3 and 
4. 
 
We compared the CSF in patients with central or peripheral (190 vs 103 patients) PNS. When 
the CSF study was done within 3 months after neurological onset (central –n=115-, peripheral – n=45- ) 
pleiocytosis was more pronounced in central PNS than in peripheral PNS (median: 6 vs 3 cells/mm3; 
Mann-Whitney-Wilcoxon test, p=0.14), while proteinorachia showed the opposite figure (median 68 vs 
100 mg/dl; Mann-Whitney-Wilcoxon test, p<0.01). The percentage of positive OCB was the same 
between central and peripheral PNS (35% vs 41%).  
 
We then wondered whether pleiocytosis and protein at time of diagnosis could have a 
prognostic value in paraneoplastic patients (figure 2). To address this issue, we selected the anti-Hu 
patients (the other antibodies were not studied because of the low number of patients) who had a CSF 
study within 3 months from clinical onset (n=92). Patients were divided into two groups; those with a 
normal cell count in the CSF (n=56) and those with more than 5 cells/mm3 (n=35). The clinical 
characteristics that are known to be of prognostic value were similar in both groups. The median Rankin 
score was 3 at time of neurological onset in both groups. PEM was as frequent in both groups (23% vs. 
18%, respectively). Peripheral disorders were slightly lower in patients with pleiocytosis (37% vs. 47% 
respectively). The median age was the same in both groups (65y vs. 66y). Surprisingly, the group with 
CSF pleiocytosis showed a better median survival than the group without (572 days vs 365 days; Log-
Rank test, p=0.05). Protein levels were not correlated with survival (data not shown). 
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Discussion  
 
Paraneoplastic Neurological Syndromes (PNS) are believed to be immune mediated. 
Inflammation of the CSF is a common finding in that setting, but no dedicated study has been published 
so far. Here we report the largest CSF study in PNS, showing that abnormal CSF is almost always seen 
in these patients, especially early in the course of the disease.  
 
Abnormal CSF was recorded in most patients (93%). This figure fits with the limited CSF data 
published in series of paraneoplastic patients with anti-Hu (Dalmau et al, 1992), anti-Yo (Peterson et al, 
1992), anti CV2/CRMP5 (Yu et al, 2001), anti-Ta (Dalmau et al, 2004), anti-Tr (Bernal and al, 2003) or 
anti-Ri antibodies (Pittock and al, 2003), with a frequency of abnormal CSF ranging from 59 and 86% of 
patients. The presence of OCB in CSF has been reported in approximately 75% of the patients with 
paraneoplastic diseases (Peterson et al, 1992; Dalmau et al, 1992; Gultekin et al, 2000; Dalmau et al, 
2004), and their specificity against the paraneoplastic antigens have been documented (Rauer et 
Kaiser, 2000; Stich et Rauer, 2007). However, the unclear status of the serum OCB in the medical 
records of our CSF study represents a methodological limitation, as intrathecal antibody synthesis 
cannot be stated. Indeed, positive OCB in the serum, related or not to the paraneoplastic disease, could 
have passively diffused into the CSF (Deisenhammer et al, 2006). 
 
In our series, pleiocytosis was more frequent in patients in whom the CSF study was done early 
after neurological onset. The median level of cells was 5 white cells/mm3 before the 3
rd
 month and 2 
white cells/mm3 after. The incidence for proteinorachia also decreased but stayed at abnormal levels 
(median level 73 mg/dl before the 3
rd
 month and 59 mg/dl after). This evolution fits with the acute or 
sub-acute course of the disease, with early neuronal loss during the first months, followed by a non-
inflammatory phase when all neurons have disappeared. However, a potential bias in the decrease over 
time of pleiocytosis can be advocated. One can imagine that patients with highly inflammatory diseases 
have a CSF study early in the evolution, while those with a poorly active or atypical disease, have a 
CSF study later on. Serial CSF analysis in a prospective study should easily exclude this hypothesis. In 
our study, when several CSF studies were available, increase in pleiocytosis was more frequent in 
patients in whom both CSF studies were done within the first 3 months, compared to patients with a 
second CSF done after 3 months. However, the median time point of the first CSF study was different 
between both groups and might have introduced a bias.  
 
 Psimaras et al, Page 9   
The inflammatory CSF, especially during the acute stage, is in line with radiological and 
pathological studies. Hypermetabolism in FDG-Pet scan and increased perfusion on SPECT have been 
described in paraneoplastic limbic encephalitis and paraneoplastic cerebellar degeneration (Choi et al, 
2006), attributed by the authors to inflammatory changes. Neuropathological studies of PCD performed 
within 1 year after the onset of neurological symptoms generally show severe loss of Purkinje cells in 
combination with various degrees of inflammatory, mainly lymphocytic, infiltrates, while studies 
performed more than 1 year after the onset showed absence of inflammatory infiltrates (Giometto et al, 
1997).  This early inflammation suggests that an early treatment might be beneficial for the clinical 
outcome.  
 
Several unexpected results were found in our study. The CSF profile was quite similar in all 
antibody types, cancers or neurological features of the PNS; although there was a trend for higher 
protein levels in patients with anti-Hu abs, SCLC and peripheral disorders, this did not reach statistical 
significance. In addition, the CSF features were similar regardless of whether the patients were treated 
(cancer or immunomodulatory treatments) before CSF study or not. This probably reflects the poor 
efficacy of the currently available treatments. 
 
However, the most intriguing finding of our study is the shorter survival of anti-Hu patients with 
low CSF inflammation when compared to patients with pleiocytosis, although both groups showed 
similar clinical characteristics, including Rankin scores. This cannot be explained by imbalanced delays 
from onset to CSF study between both groups, since we selected only the patients who had a lumbar 
puncture within 3 months after neurological onset. Obviously, due to the limited number of patients, this 
result needs to be confirmed in a large prospective study. This better survival could be related to a 
slower tumour growth and/or better tumour response in patients who developed a strong immune 
response. This could also be related to greater sensitivity to immunological treatment in patients with a 
high inflammatory response, as reported in neurosarcoidosis (Hoitsma E et al, 2004) or even in multiple 
sclerosis (Polman for AFFIRM study, 2006 and Jacobs for CHAMPS study, 2000).  
 
In conclusion, CSF inflammation is very common in PNS patient and could be a helpful 
diagnostic tool, especially if this analysis is done within 3 months after neurological onset. Preliminary 
data show that patients with pleiocytosis at the time of diagnosis might have a better survival, but this 
finding should be confirmed in a larger, prospective study.  
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Legends to tables and figures 
 
 
Table 1: Patient characteristics (F/M: female/male, PEM: paraneoplastic encephalomyelitis, SCLC: 
small cell lung cancer, NSCLC: no small cell lung cancer, CSF: cerebrospinal fluid).  
 
Table 2: Q1 is the first quartile (id 25% of patients are under Q1). Q3 is the third quartile (id 75% of 
patients are under Q3). 
 
Figure 1: evolution over time after neurological onset of cells and proteins in cerebrospinal fluids. 
 
Figure 2: survival of patients with anti-Hu antibodies who had a CSF study within 90 days after 
neurological onset. Patients were divided into 2 groups; those with a normal cell count in the CSF 
(black; n=56) and those with more than 5 white cells/mm3 (grey; n=35). The group with CSF 
inflammation showed a better median survival than the group without (572 days vs 365 days, p= 0,05).  
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Appendix 5: Cell numbers in the CSF (cells/mm3) in the patients who had repeated CSF 
studies without any treatment between two CSF tests. 
 
 
both CSF analysis before  day 90 (n=15) second CSF analysis after  day 90 (n=17)
median cell number at  first CSF study 9 7
median cell number at second CSF study 20 2
normal cell numbers in both CSF 3 patients 6 patients
decrease in pleiocytosis between both CSF 5 patients  10 patients
 increase in pleiocytosis between both CSF 7 patients 1 patient
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Appendix 3 and 4
Anti-Hu Anti-Yo
Anti-
CV2
Anti-
Ma/Ta
Anti-Ri Anti-Tr
Cells ≥ 5 
wc/mm3
38% 57% 50% 75% 57% 67%
Protein > 50 
mg/dl
80% 54% 82% 71% 50% 50%
Positive 
oligoclonal 
bands
20/34 15/19 2/4 2/4 3/4 0/2
SCLC NSCLC
Testicular
Cancer
Breast
Cancer
Gynecol
ogical
Cancer
Hodgkin
Lymphoma
Cells ≥ 5 
wc/mm3
40% 29% 100% (2/2) 43% 65% 50%
Protein > 50 
mg/dl
83% 83% 100% (2/2) 44% 48% 25%
Positive 
oligoclonal 
bands
16/28 1/3 1/1 3/6 10/11 0/2
